Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medical Imaging
Published in: BMC Medical Imaging 1/2020

01-12-2020 | Lymphoma | Research article

Performance of diffusion and perfusion MRI in evaluating primary central nervous system lymphomas of different locations

Authors: Zhen Xing, Nannan Kang, Yu Lin, Xiaofang Zhou, Zebin Xiao, Dairong Cao

Published in: BMC Medical Imaging | Issue 1/2020

Login to get access

Abstract

Background

Diffusion and perfusion MRI can invasively define physical properties and angiogenic features of tumors, and guide the individual treatment. The purpose of this study was to investigate whether the diffusion and perfusion MRI parameters of primary central nervous system lymphomas (PCNSLs) are related to the tumor locations.

Methods

We retrospectively reviewed the diffusion, perfusion, and conventional MRI of 68 patients with PCNSLs at different locations (group 1: cortical gray matter, group 2: white matter, group 3: deep gray matter). Relative maximum cerebral blood volume (rCBVmax) from perfusion MRI, minimum apparent diffusion coefficients (ADCmin) from DWI of each group were calculated and compared by one-way ANOVA test. In addition, we compared the mean apparent diffusion coefficients (ADCmean) in three different regions of control group.

Results

The rCBVmax of PCNSLs yielded the lowest value in the white matter group, and the highest value in the cortical gray matter group (P < 0.001). However, the ADCmin of each subgroup was not statistically different. The ADCmean of each subgroup in control group was not statistically different.

Conclusion

Our study confirms that rCBVmax of PCNSLs are related to the tumor location, and provide simple but effective information for guiding the clinical practice of PCNSLs.
Literature
1.
Koeller KK, Smirniotopoulos JG, Jones RV. Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics. 1997;17(6):1497–526.CrossRef
2.
McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000;46(1):51–60 discussion 60-51.CrossRef
3.
Momota H, Narita Y, Maeshima AM, Miyakita Y, Shinomiya A, Maruyama T, Muragaki Y, Shibui S. Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma. J Neuro-Oncol. 2010;98(3):341–8.CrossRef
4.
Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83(3):235–9.CrossRef
5.
Kansara R, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D. Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol. 2015;90(12):1149–54.CrossRef
6.
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071–121.CrossRef
7.
Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107(9):3716–23.CrossRef
8.
Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA. Differential gene expression in central nervous system lymphoma. Blood. 2009;113(1):266–7 author reply 267-268.CrossRef
9.
Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, Kim JH, Yun TJ, Chang KH. Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade. Radiology. 2011;261(3):882–90.CrossRef
10.
Yan R, Haopeng P, Xiaoyuan F, Jinsong W, Jiawen Z, Chengjun Y, Tianming Q, Ji X, Mao S, Yueyue D, et al. Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index. Neuroradiology. 2016;58(2):121–32.CrossRef
11.
Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2010;31(1):60–6.CrossRef
12.
Zhang Y, Zhang Q, Wang XX, Deng XF, Zhu YZ. Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment. Clin Radiol. 2016;71(10):1018–29.CrossRef
13.
Huang WY, Wen JB, Wu G, Yin B, Li JJ, Geng DY. Diffusion-weighted imaging for predicting and monitoring primary central nervous system lymphoma treatment response. AJNR Am J Neuroradiol. 2016;37(11):2010–8.CrossRef
14.
Nagesh V, Chenevert TL, Tsien CI, Ross BD, Lawrence TS, Junck L, Cao Y. Quantitative characterization of hemodynamic properties and vasculature dysfunction of high-grade gliomas. NMR Biomed. 2007;20(6):566–77.CrossRef
15.
Seeger A, Braun C, Skardelly M, Paulsen F, Schittenhelm J, Ernemann U, Bisdas S. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease. Acad Radiol. 2013;20(12):1557–65.CrossRef
16.
Barajas RF Jr, Phillips JJ, Vandenberg SR, McDermott MW, Berger MS, Dillon WP, Cha S. Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI. Clin Radiol. 2015;70(10):1087–95.CrossRef
17.
Cha S. Perfusion MR imaging: basic principles and clinical applications. Magn Reson Imaging Clin N Am. 2003;11(3):403–13.CrossRef
18.
Bjornerud A, Sorensen AG, Mouridsen K, Emblem KE. T1- and T2*-dominant extravasation correction in DSC-MRI: part I--theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab. 2011;31(10):2041–53.CrossRef
19.
Ginat DT, Mangla R, Yeaney G, Schaefer PW, Wang H. Correlation between dynamic contrast-enhanced perfusion MRI relative cerebral blood volume and vascular endothelial growth factor expression in meningiomas. Acad Radiol. 2012;19(8):986–90.CrossRef
20.
Ho CY, Cardinal JS, Kamer AP, Kralik SF. Relative cerebral blood volume from dynamic susceptibility contrast perfusion in the grading of pediatric primary brain tumors. Neuroradiology. 2015;57(3):299–306.CrossRef
21.
Zhang D, Hu LB, Henning TD, Ravarani EM, Zou LG, Feng XY, Wang WX, Wen L. MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol. 2010;11(3):269–77.CrossRef
22.
Lu SS, Kim SJ, Kim N, Kim HS, Choi CG, Lim YM. Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions. AJR Am J Roentgenol. 2015;204(4):827–34.CrossRef
23.
Schob S, Meyer J, Gawlitza M, Frydrychowicz C, Müller W, Preuss M, Bure L, Quäschling U, Hoffmann KT, Surov A. Diffusion-weighted MRI reflects proliferative activity in primary CNS lymphoma. PLoS One. 2016;11(8):e0161386.CrossRef
24.
Surov A, Gottschling S, Mawrin C, Prell J, Spielmann RP, Wienke A, Fiedler E. Diffusion-weighted imaging in meningioma: prediction of tumor grade and association with Histopathological parameters. Transl Oncol. 2015;8(6):517–23.CrossRef
25.
Schob S, Meyer HJ, Dieckow J, Pervinder B, Pazaitis N, Höhn AK, Garnov N, Horvath-Rizea D, Hoffmann KT, Surov A. Histogram Analysis of Diffusion Weighted Imaging at 3T is Useful for Prediction of Lymphatic Metastatic Spread, Proliferative Activity, and Cellularity in Thyroid Cancer. Int J Mol Sci. 2017;18(4):821.
26.
Valles FE, Perez-Valles CL, Regalado S, Barajas RF, Rubenstein JL, Cha S. Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2013;34(1):35–40.CrossRef
27.
Goyal P, Kumar Y, Gupta N, Malhotra A, Gupta S, Gupta S, Mangla M, Mangla R. Usefulness of enhancement-perfusion mismatch in differentiation of CNS lymphomas from other enhancing malignant tumors of the brain. Quant Imaging Med Surg. 2017;7(5):511–9.CrossRef
28.
Nakajima S, Okada T, Yamamoto A, Kanagaki M, Fushimi Y, Okada T, Arakawa Y, Takagi Y, Miyamoto S, Togashi K. Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI. Clin Radiol. 2015;70(12):1393–9.CrossRef
29.
Xing Z, You RX, Li J, Liu Y, Cao DR. Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Clin Neuroradiol. 2014;24(4):329–36.CrossRef
30.
Toh CH, Wei KC, Chang CN, Ng SH, Wong HF. Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction. AJNR Am J Neuroradiol. 2013;34(6):1145–9.CrossRef
31.
Kuppusamy K, Lin W, Cizek GR, Haacke EM. In vivo regional cerebral blood volume: quantitative assessment with 3D T1-weighted pre- and postcontrast MR imaging. Radiology. 1996;201(1):106–12.CrossRef
32.
Ferreri AJ, Marturano E. Primary CNS lymphoma. Best Pract Res Clin Haematol. 2012;25(1):119–30.CrossRef
33.
Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus. 2006;21(5):E1.CrossRef
34.
Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26(15):2512–8.CrossRef
35.
Chung SR, Choi YJ, Kim HS, Park JE, Shim WH, Kim SJ. Tumor vascular permeability pattern is associated with complete response in Immunocompetent patients with newly diagnosed primary central nervous system lymphoma: retrospective cohort study. Medicine. 2016;95(6):e2624.CrossRef
36.
Jahnke K, Doolittle ND, Muldoon LL, Neuwelt EA. Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus. 2006;21(5):E11.CrossRef
Metadata
Title
Performance of diffusion and perfusion MRI in evaluating primary central nervous system lymphomas of different locations
Authors
Zhen Xing
Nannan Kang
Yu Lin
Xiaofang Zhou
Zebin Xiao
Dairong Cao
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Medical Imaging / Issue 1/2020
Electronic ISSN: 1471-2342
DOI
https://doi.org/10.1186/s12880-020-00462-7

Other articles of this Issue 1/2020

BMC Medical Imaging 1/2020 Go to the issue

Research article

Performance of TGSE BLADE DWI compared with RESOLVE DWI in the diagnosis of cholesteatoma

Research article

Percentage fat fraction in magnetic resonance imaging: upgrading the osteoporosis-detecting parameter

Case report

Application of contrast-enhanced ultrasonography for large cell neuroendocrine carcinoma in the urinary bladder: a case report

Case report

A case with Behçet’s disease involving erosive Metacarpophalangeal joint arthritis: the value of ultrasonography in the diagnosis of an Erosion

Research article

Prevalence and predictors of alternative diagnoses on whole-leg ultrasound negative for acute deep venous thrombosis

Research article

Patient-adapted organ absorbed dose and effective dose estimates in pediatric 18F-FDG positron emission tomography/computed tomography studies